

# rTMS in the treatment of drug addiction: An update about human studies

Elisa Bellamoli<sup>a,b,\*</sup>, Paolo Manganotti<sup>b</sup>, Robert P. Schwartz<sup>c</sup>, Claudia Rimondo<sup>d</sup>,  
Maurizio Gomma<sup>a</sup> and Giovanni Serpelloni<sup>e</sup>

<sup>a</sup>Addiction Department, ULSS 20, Verona, Italy

<sup>b</sup>Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Verona, Italy

<sup>c</sup>Friends Research Institute, Baltimore, Maryland

<sup>d</sup>National Coordination Centre for NIDA Collaborations, Verona, Italy

<sup>e</sup>Department for Anti-Drug Policies, Presidency of Ministers' Council of Italy, Italy

**Abstract.** Drug addiction can be a devastating and chronic relapsing disorder with social, psychological and physical consequences, and more effective treatment options are needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has been assessed in a growing number of studies for its therapeutic potential in treating addiction. This review paper offers an overview on the current state of clinical research in treating drug addiction with rTMS. Because of the limited research in this area, all studies (including case reports) that evaluated the therapeutic use of rTMS in nicotine, alcohol or illicit drug addiction were included in this review. Papers published prior to December 2012 were found through an NCBI PubMed search (<http://www.ncbi.nlm.nih.gov>). A total of eleven studies were identified that met review criteria. There is nascent evidence that rTMS could be effective in reducing cocaine craving, and nicotine and alcohol craving and consumption, and might represent a potential therapeutic tool for treating addiction. Further studies are needed to identify the optimal parameters of stimulation for the most effective treatment of drug addiction, to improve our comprehension of the treatment neurophysiological effects, and to conduct rigorous, controlled efficacy studies with adequate power.

**Keywords:** Repetitive transcranial magnetic stimulation (rTMS), addiction, nicotine, alcohol, cocaine

## 1. Introduction

Psychoactive drugs act on the central nervous system and recurring drug intoxication can result in addiction, a complex disease process of the brain which can be treated [1]. Addiction can be described as a persistent state in which there is reduced capacity to control compulsive drug-seeking, regardless of whether it involves risk of negative consequences [2,3]. It is often a devastating and chronically relapsing disorder with social, psychological and physical consequences. Drug

addiction incurs enormous medical, economic and social costs. The currently available treatment options for addiction remain somewhat limited and long-term success rates are modest [4].

Brain stimulation allows modulation of activity in specific brain regions. Recently, non-surgical brain stimulation techniques have been utilized in examining the effects of drug administration on cortical activity in order to further explore the effects of repeated drug use on cortical excitability. Furthermore, several novel studies have begun to assess brain stimulation as a potential treatment for reducing addictive behaviours [5].

This review paper offers an overview on the current state of research in treating addiction in humans with Transcranial Magnetic Stimulation (TMS), a non-

\*Corresponding author: Elisa Bellamoli, Dipartimento delle Dipendenze ULSS 20, Via Germania 20 – 37136 Verona, Italy. Tel.: +39 045 8076246; Fax: +39 045 8622239; E-mail: [ebellamoli@dronet.org](mailto:ebellamoli@dronet.org).

invasive brain stimulation technique that may have therapeutic potential in treating addiction.

Due to the limited amount of research in this area, all studies (including case reports) that were identified through an NCBI PubMed search (<http://www.ncbi.nlm.nih.gov>), were included in the review if published prior to December 2012 and if reporting on the evaluation of the therapeutic use of rTMS in tobacco, alcohol or illicit drug addiction. Search terms included “repetitive transcranial magnetic stimulation”, “rTMS”, with adjoining terms “addiction”, “drug”, “nicotine”, “tobacco”, “alcohol”, “cocaine”, “opioids”, “heroin”, “cannabis”, “marijuana”, “MDMA”, “ecstasy”. A total of 11 studies were identified and included in this review and were classified according to the system reported by Brainin et al. [67] for the European Federation of Neurological Societies. In this system, individual studies are rated on a continuum based on the level of evidence, as follows: Class I requires a rigorously conducted randomized clinical trial (RCT); Class II requires a less rigorously conducted RCT or a prospective matched-group cohort study; Class III requires any other type of controlled trial (Class III); and, Class IV requires uncontrolled studies, case series, case reports, or expert opinion. Based on the evidence, the approaches are then rated in three levels: Level A indicates the approach is effective, ineffective, or harmful if there is at least one Class I study or two Class II studies; Level B indicates the approach is probably effective, ineffective, or harmful if there is at least one convincing Class II study or overwhelming Class III evidence; and, Level C indicates the approach is possibly effective, ineffective, or harmful if there are at least two convincing class III studies.

## 2. Transcranial magnetic stimulation

TMS is a non-surgical brain stimulation technique that is proving to be valuable for both its research and therapeutic potential within psychiatry [6]. TMS is able to modulate cortical excitability and it is used to facilitate functional brain mapping of cortical regions [7]. It uses a magnetic pulse of high intensity, focused in a limited area, which is administered through a coil. The extremely fast passage of electric current in the coil induces a transient, high-intensity magnetic pulse that penetrates through the scalp and reaches the underlying cortex. In the targeted cortical area, the magnetic pulse generates an electric current that induces depolarization of superficial cortical neurons [8].

In the region beneath the coil and interconnected areas occurs a stimulation or a disruption of local neural activity [9,10].

Repetitive TMS (rTMS) is used to induce longer lasting alterations, facilitation or functional disruptions. In rTMS, trains of several pulses are delivered using various stimulation patterns [11]. It provides a repeated stimulation of the scalp at the same point with a frequency ranging from 1 to 20 Hz or more. The parameters in rTMS include its intensity, frequency, length of trains of pulses and time interval between trains. The effects of rTMS are longer than TMS single pulse. These long-term changes in the functioning of the cortex produce effects that vary depending on the frequency of stimulation, resulting in inhibition or facilitation.

While the long-lasting neurophysiologic effects of rTMS are poorly understood, several studies showed that rTMS can induce significant and long-lasting behavioural alterations, including reduction in craving and consumption of drugs of abuse.

The safety of TMS has been reported in a number of studies [12–14] and the most recent guidelines for its use have been published in 2009 by Rossi and colleagues [15]. The use of TMS is generally not recommended with patients who have a history of epilepsy, in carriers of pacemaker, hearing aids, metal in any part of the body, and in pregnant women. Single pulses or low frequency stimulation appears to carry little risk beyond occasionally causing local discomfort at the site of stimulation. In some circumstances, especially when the intensity of the magnetic pulse is high, the effect of current induced by the magnetic field can spread to the surrounding muscles on the head and neck, causing contractions. Occasionally, mild or moderate transient headache have been reported. Long-term effects of repeated rTMS sessions are as yet unknown. Based on existing data, rTMS appears safe when administered according to recommended guidelines, and its safety record supports its further development as a clinical treatment [14,16].

## 3. TMS and cortical excitability in addiction: Physiopathological mechanisms

There were some reports of using TMS to measure cortical inhibition in the cerebral cortex of subjects with substance dependence [17–27]. These studies found that chronic exposure to various addictive drugs induces alterations in cortical excitability in

122 the motor, occipital and prefrontal cortex (PFC). Cortical  
123 conductivity has been evaluated in individuals  
124 with exposure to alcohol [17–21], with nicotine de-  
125 pendence [22], with chronic cannabis exposure [23],  
126 with chronic ecstasy exposure [24], and cocaine addic-  
127 tions [25–27].

128 Decreased excitability in the motor cortex was found  
129 in individuals who are cocaine [25–27] and nicotine  
130 dependent [22]. Chronic cannabis use is associated  
131 with a reduction in cortical inhibition [23]. Increased  
132 excitability of the visual cortex was found in individu-  
133 als with chronic MDMA use, abstinent for 3 days [24].  
134 Acute alcohol exposure was found to be associated  
135 with decreased excitability in the motor cortex [17,18]  
136 and the PFC [19]. Moreover, Conte et al. [20] proposed  
137 that while acute ethanol administration seemed to af-  
138 fect GABA neurotransmission, chronic administration  
139 appeared to alter the glutamate mechanisms involved  
140 in cortical excitability. Nardone and colleagues [21]  
141 found that TMS showed a selective increase in in-  
142 tracortical facilitation after ethanol withdrawal which  
143 supported the theory that altered glutamatergic recep-  
144 tor function plays an important role in the pathogene-  
145 sis of human alcohol withdrawal [21]. Impaired corti-  
146 cal inhibition has been reported in persons exposed to  
147 substances of abuse, suggesting that abnormal cortical  
148 excitability may reflect changes in the brain systems of  
149 GABA and glutamate [5].

150 These findings are important as they indicate altered  
151 cortical excitability in drug dependent populations and  
152 suggest that TMS can be utilized as an investigative  
153 tool to better understand the pathophysiology of ad-  
154 diction. Nevertheless, these studies have several limi-  
155 tations. First, these were exploratory studies with small  
156 samples. Second, it is difficult to determine whether al-  
157 terations in the corticospinal measures are a direct re-  
158 sult of chronic drug administration, or rather, occur due  
159 to pre-existing vulnerabilities, or perhaps even a com-  
160 bination of both. Finally, poly-substance use and/or a  
161 comorbid psychiatric condition could also exacerbate  
162 these alterations in cortical excitability.

#### 163 4. rTMS as a therapeutic tool

164 Repetitive TMS can modulate the excitability of  
165 stimulated cortex and interconnected brain regions,  
166 even after the period of stimulation [10,11,28]. It has  
167 been reported that high frequency rTMS (> 5 Hz) tran-  
168 siently increases cortical excitability [29,30]. Changes  
169 in neurotransmission induced by rTMS have been ob-

170 served in both animal [31,32] and human studies [33,  
171 34]. rTMS over the PFC seems to have modulator ef-  
172 fect on mesolimbic and mesostriatal dopaminergic sys-  
173 tems. Strafella et al. [33] found that high frequency  
174 rTMS on the prefrontal cortex in humans induces sub-  
175 cortical release of dopamine in caudate nucleus. Cho  
176 and Strafella [34] showed that rTMS over the left  
177 DLPFC modulates the release of dopamine in anterior  
178 cingulated cortex and orbitofrontal cortex in the same  
179 hemisphere.

180 The effect of rTMS on dopaminergic neurotransmis-  
181 sion and cortical excitability suggests that this tech-  
182 nique can be used in the study and treatment of vari-  
183 ous neuropsychiatric disorders associated with abnor-  
184 mal dopamine activity and altered cortical excitabil-  
185 ity, such as depression [35–38], obsessive-compulsive  
186 disorder [39,40], schizophrenia [41–44] and drug ad-  
187 diction [45–55]. The efficacy of administering TMS  
188 protocols, to frontal brain areas, as a potential non-  
189 pharmacological candidate for increasing dopamine  
190 levels in the mesocorticolimbic circuitry and altering  
191 neuroadaptations induced by chronic drug use has been  
192 assessed with animal studies [5].

#### 193 5. rTMS in the treatment of addiction: The 194 rationale and experimental evidence

195 Recent studies have begun to assess the effects of  
196 rTMS on addictive behaviours in humans. Repeated  
197 exposure to drugs can cause long-term neural adap-  
198 tations in some systems. These neuroadaptations are  
199 partly associated with altered dopamine activity in  
200 the mesocorticolimbic circuitry [56,57], and lead to  
201 an alteration of glutamate neurotransmission [58] and  
202 cortical excitability [59,60], which have been impli-  
203 cated in the persistence of drug-seeking behaviours, in-  
204 creased difficulties regulating drug-seeking behavior,  
205 and a heightened likelihood of relapse [61].

206 Because rTMS can affect cortical excitability and  
207 increase the release of dopamine in the mesolimbic  
208 dopaminergic system, it is thought that repeated appli-  
209 cations of rTMS may affect neuroadaptation induced  
210 by the chronic use of substances. In addition, rTMS  
211 can modulate neuronal activity and, thus, at least in-  
212 duce acute effects on circuitries that mediate differ-  
213 ent behaviours. Repeated sessions of rTMS of the  
214 PFC are, therefore, suggested to reduce drug craving,  
215 drug-seeking and eventually drug consumption and re-  
216 lapse [47].

217 There is accumulating evidence that stimulating the  
218 dorsolateral part of the prefrontal cortex (DLPFC)

may be of use in addiction treatment. DLPFC is involved in the decision-making processes [62] and these processes can be altered by rTMS [63]. Addiction is associated with increased impulsivity and willingness to take risks, which in turn can lead to impaired decision-making [64]. rTMS on the DLPFC could modulate these decision-making processes in addiction and thereby reduce impulsivity and enhance inhibitory control, which may lead to a reduction in the use of substances. Therefore, the neuropsychological assumption underlying research using rTMS in the treatment of addiction is that exciting the DLPFC by high frequency pulses, should increase its activity and increase its inhibitory control function. In particular, with drug-addicted subjects, this treatment should increase DLPFC function to cope with drug craving. In fact, to date, several human studies have evaluated the effects of rTMS protocols on drug craving, a major component determining relapse, and consumption in nicotine [45–49], alcohol [50–53] and cocaine [54,55] dependent groups.

The following section describes studies which have explored the therapeutic potential of rTMS in reducing addictive behaviours within substance dependent populations.

### 5.1. rTMS and nicotine

Five papers which examined rTMS and nicotine dependence are summarized below and in Table 1.

Johann et al. [45] and Eichhammer et al. [46] investigated with exploratory studies whether high frequency rTMS of DLPFC could decrease nicotine-seeking related behaviours. In the first pilot double-blind cross-over study, Johann et al. [45] investigated whether rTMS of the DLPFC could modulate levels of tobacco craving. Eleven treatment-seeking smokers under 12 hour abstinent conditions were administered either one active or one sham session of 20 Hz rTMS over the left DLPFC at 90% of MT. The session consisted of 20 trains of stimuli of 2.5 s. The levels of tobacco craving were assessed using a 100-point visual analogue scale (VAS) both 30 minutes prior to and following the rTMS treatment. rTMS significantly reduced the level of tobacco craving reported 30 minutes following the treatment [45]. These findings, therefore, motivated further investigation on the efficacy of rTMS as a potential treatment in nicotine dependence to reduce not only the level of craving but also of smoking consumption.

Following this pilot study, the same research group [46] investigated the effects of two sessions of

active and sham rTMS at the same parameters with a double-blind cross-over design study. Participants consisted of 14 treatment-seeking tobacco dependents. All participants were required to abstain from smoking 12 hours before the rTMS sessions. In a randomized order, each participant received 2 active trials and 2 sham stimulation sessions over 4 consecutive days. Smoking craving was measured at baseline and 30 min after the rTMS session using a VAS. In addition, the number of cigarettes freely smoked in a 6-hour time period following treatment was recorded. During this 6 hour time period, the number of cigarettes smoked following high frequency rTMS applied to the left DLPFC was significantly decreased, but craving levels remained unchanged. The authors have suggested that the evaluation of craving may have not been sensitive enough and that the sample size was probably too small to detect alterations in craving [46]. Treatment with high-frequency rTMS was, therefore, found to decrease craving level for tobacco in the pilot study, although this finding was not replicated in the second study. The second study demonstrated reduced smoking consumption following rTMS session, thus contributing to the preliminary evidence of the utility of rTMS treatment in nicotine dependence [65]. Based on these findings, the authors propose that high frequency rTMS could have potential therapeutic value in the treatment of nicotine dependence through a reduction in the levels of craving [45] and its consumption [46].

Amiaz et al. [47] were also interested in evaluating the effects of high frequency rTMS of the left DLPFC, combined with either smoking or neutral cues, on cigarette consumption, dependence and craving. The researchers expanded on the previous two studies by assessing whether exposure to smoking cues (prior to the stimulation) could modulate the effect of rTMS. They postulated that in addition to the effect of rTMS on dopamine transmission and cortical excitability, rTMS over the PFC may disrupt craving-related circuitries and that this effect would be prominent when rTMS is applied immediately after activation of such circuitry by smoking cues. Forty-eight heavy smokers motivated to quit smoking were recruited for the study. Participants were randomly divided into real and sham stimulation groups. Each group was subdivided randomly into two subgroups presented with either smoking-related or neutral cues just before the daily TMS intervention. Thus, there were four experimental groups: active TMS with smoking pictures, active TMS with neutral pictures, sham TMS with smoking

320 pictures and sham TMS with neutral pictures. The au- 371  
321 thors assessed the effects of 10 days of treatment with 372  
322 either active or sham 10 Hz rTMS treatment applied to 373  
323 the left DLPFC. Daily rTMS sessions were applied ev- 374  
324 ery week-day and then a maintenance phase was con- 375  
325 ducted in which rTMS sessions were less frequent. 376  
326 Ten daily sessions of high frequency (10 Hz) rTMS 377  
327 over the left DLPFC were administered in an attempt 378  
328 to induce long-lasting effects. Stimulation included 379  
329 20 trains/day at 100% of MT and each train consisted 380  
330 of 50 pulses at 10 Hz with an inter-train interval of 15 s. 381  
331 Prior to the rTMS, participants were exposed to either 382  
332 smoking or neutral visual cues. Cigarette consump- 383  
333 tion was evaluated objectively by measuring cotinine 384  
334 (a metabolite of nicotine) urine levels before the first 385  
335 and the 10th treatment, and participants were admin- 386  
336 istered standard questionnaires on nicotine consump- 387  
337 tion, craving and dependence. VAS was used to evalu- 388  
338 ate levels of nicotine craving before and after the pre- 389  
339 sentation of the smoking or the neutral cues and af- 390  
340 ter rTMS administration. rTMS, independent of expo- 391  
341 sure to smoking pictures, reduced subjective and ob- 392  
342 jective measures of cigarette consumption and nico- 393  
343 tine dependence. It also reduced cue-induced craving 394  
344 and blocked the development of general craving in- 395  
345 duced by repeated presentation of smoking-related pic- 396  
346 tures. However, these effects tended to dissipate after 397  
347 the 10 daily sessions and the reduction in cigarette con- 398  
348 sumption was not significant 6 months after treatment 399  
349 termination. Interestingly, there was a trend for lower 400  
350 cigarette consumption in the active rTMS-smoking 401  
351 picture group at 6 month follow-up. Overall, results 402  
352 from this study suggested that high frequency rTMS 403  
353 over the DLPFC reduced cigarette consumption and 404  
354 nicotine dependence [47]. 405

355 Wing et al. [48] examined the efficacy of high 406  
356 frequency rTMS for smoking cessation in treatment- 407  
357 seeking individuals with schizophrenia, a population of 408  
358 smokers who are typically highly nicotine-dependent. 409  
359 These authors completed a 10-week, randomized, dou- 410  
360 ble-blind, sham-controlled trial of rTMS (20 sessions; 411  
361 5 treatments/week in Weeks 1–4) as an adjunct to 412  
362 weekly group therapy and transdermal nicotine (TN; 413  
363 21 mg) provided in Weeks 3–9 in 15 heavily-dependent 414  
364 smokers ages 18 to 60 with schizophrenia or schizoaf- 415  
365 fective disorder. They were motivated to quit within 416  
366 the next month and the target quit date was the start 417  
367 of Week 3. Subjects were randomly assigned to re- 418  
368 ceive active ( $N = 6$ ) or sham ( $N = 9$ ) rTMS. Bi- 419  
369 lateral rTMS (randomized and counterbalanced) was 420  
370 administered to the DLPFC. 20 Hz stimulation was 421

administered at 90% of the resting motor threshold 371  
for 25 trains (30 pulses/train; 30 s intertrain interval; 372  
750 pulses/hemisphere). Sham stimulation was admin- 373  
istered in the single-wing tilt position. Smoking (self- 374  
report and breath carbon monoxide [CO] levels), psy- 375  
chiatric measures (Positive and Negative Syndrome 376  
Scale [PANSS]), and adverse events were assessed 377  
weekly. Craving, using the Tiffany Questionnaire for 378  
Smoking Urges (TQSU), and withdrawal, using the 379  
Minnesota Nicotine Withdrawal Scale, were assessed 380  
pre- and post-rTMS once during each treatment week. 381

Consistent with findings in non-psychiatric smok- 382  
ers [45], pre- and post-rTMS data collected in Week 383  
1 showed that treatment with rTMS significantly re- 384  
duced craving. While there was a robust increase in 385  
craving following the rTMS session in the sham group 386  
(due to abstinence from smoking), post-treatment crav- 387  
ings in the active group were the same or lower than 388  
the pre-treatment assessment. rTMS did not alter crav- 389  
ing in Weeks 2–4. As short-term smoking abstinence 390  
did not increase craving in these weeks, data obtained 391  
in Week 1 likely provides the most sensitive measure- 392  
ment of rTMS effects on craving. Despite attenuation 393  
of tobacco craving, rTMS did not increase abstinence 394  
rates. An increased number of rTMS sessions may be 395  
needed for the effects on craving to translate to effects 396  
on smoking [48]. 397

Rose et al. [49], instead, investigated the rTMS ef- 398  
fects over Superior Frontal Gyrus (SFG), a specific 399  
prefrontal cortex region, which supports cue-induced 400  
craving. They implemented a within-subject design to 401  
examine subjective responses to smoking versus neu- 402  
tral cues and to controlled presentations of cigarette 403  
smoke. Fifteen smokers were recruited for study par- 404  
ticipation and were exposed to three conditions on dif- 405  
ferent days: 1) high frequency rTMS (10 Hz) over Su- 406  
perior Frontal Gyrus (SFG), a specific prefrontal cor- 407  
tex region, which supports cue-induced craving; 2) low 408  
frequency (1 Hz) rTMS over the SFG; 3) low fre- 409  
quency (1 Hz) rTMS over the motor cortex (control 410  
condition). In each condition, subjects were stimulated 411  
for three periods of 2 minutes and 30 seconds at 90% 412  
MT. The researchers evaluated craving for cigarettes 413  
and they found that compared to 1 Hz rTMS to the SFG 414  
or motor cortex, 10 Hz to the SFG resulted in increased 415  
cue-induced craving but lower craving during presen- 416  
tation of neutral cues. Craving after smoking cue pre- 417  
sentations was elevated in the 10 Hz SFG condition, 418  
whereas craving after neutral cue presentations was re- 419  
duced. Ratings of immediate craving reduction as well 420  
as the intensity of interoceptive airway sensations were 421

also attenuated upon smoking in the 10 Hz SFG condition. These findings support the idea that SFG plays a role in modulating craving reactivity, and that the SFG plays a role in both excitatory and inhibitory influences on craving but do not provide evidence for the utility of rTMS of the SFG for the treatment of tobacco addiction [49].

In summary, as shown in Table 1, the first four studies described above showed that high frequency rTMS of the DLPFC can attenuate nicotine consumption [46,47] and craving [45,48]. Rose et al. [49], instead, highlighted the excitatory and inhibitory influence of SFG on tobacco cravings but did not provide evidence for the utility of rTMS of the SFG for the treatment of tobacco addiction. However, the significance and duration of these effects are limited and further investigation is required to identify the appropriate stimulation parameters and targets. While other types of brain stimulation techniques (transcranial direct current stimulation, cranial electrostimulation, deep brain stimulation) have been evaluated in the treatment of nicotine addiction, there is the most evidence to support rTMS's potential to treat nicotine dependence [66]. According to the criteria suggested by Brainin et al. [67], the extant research on the therapeutic use of rTMS for nicotine dependence has one study in Class II [47], three studies in class III [45,46, 49] and one study in class IV [48] that showed reduction in craving, consumption and dependence. Thus, according to the available evidence, rTMS falls within the Level B recommendation as probably effective in the treatment of nicotine addiction.

## 5.2. rTMS and alcohol

Studies of rTMS in alcohol dependent individuals are summarized below and in Table 2.

Mishra et al. [50] published the first study about rTMS treatment of alcohol dependence. These authors studied the anti-craving efficacy of high frequency rTMS of the right DLPFC in a single-blind, sham-controlled study involved 45 patients with alcohol dependence. Participants were assigned to one of the two groups in which they received either real ( $N = 30$ ) or sham ( $N = 15$ ) rTMS. They were administered 10 daily sessions of high frequency (10 Hz) rTMS at 110% of MT over the right DLPFC. Each session consisted of 20 trains with 4.9 s per train and 30 s inter-train interval. The Alcohol Craving Questionnaire (ACQ-NOW) was administered in order to evaluate the extent of alcohol craving at baseline, im-

mediately after the last rTMS and a month after the last session. There was a significant reduction in the post-rTMS ACQ-NOW total score and factor scores in the group allocated to active rTMS compared to the group allocated to sham stimulation. It was found that 10 daily sessions of high-frequency rTMS over right DLPFC had significant anti-craving effects in alcohol dependence. This study supports the therapeutic potential of rTMS which, especially when combined with anti-craving drugs, could represent an effective strategy in reducing craving and alcohol relapse among alcohol dependent subjects [50].

Hoppner et al. [52] investigated the effect of high frequency rTMS of the left DLPFC compared to sham stimulation on craving and mood in alcohol dependent women. Moreover, this study examined the impact on an attentional blink (AB) paradigm to pictures with neutral, emotional and alcohol-related contents. Nineteen female detoxified participants were randomized either to a high frequency rTMS (20 Hz) over the left DLPFC ( $N = 10$ ) or a sham stimulations ( $N = 9$ ) at 10 days. Alcohol craving was assessed with the Obsessive Compulsive Drinking Scale and depressive symptoms were assessed by the Hamilton Depression Rating Scale and the Beck Depression Inventory. An age-matched control group was investigated for the AB paradigm. There were no significant differences in clinical parameters such as alcohol craving or mood after real rTMS compared to sham stimulation. In the AB paradigm, real stimulated participants detected alcohol related T2 targets incorrectly in comparison to the sham stimulated and control subjects. Although there were no differences in craving and mood after real high frequency rTMS compared to sham stimulation, an interesting difference between the real and the sham stimulated group and controls was found in the AB paradigm, suggesting an increase of the AB effect to alcohol-related pictures after real stimulation [52].

Herremans et al. [69] performed a prospective, single-blind, sham-controlled study in order to investigate the effect of single high frequency rTMS session of the right DLPFC on alcohol craving in the community. Participants ( $N = 36$ ) were hospitalized alcohol-dependent patients. After successful detoxification, participants were allocated to receive one active or one sham rTMS session. The rTMS session was administered on Friday before the weekend at home. The rTMS session consisted of 40 trains of 1.9 s at 20 Hz at 110% MT with a 12 s inter-train interval. The obsessive-compulsive drinking scale (OCDS) was administered to assess the intensity of alcohol crav-

Table 1  
Summary of the studies on rTMS in the treatment of nicotine addiction

Study	N subjects (active, sham)	Place of stimulation	Number of sessions	Length	Frequency	Intensity of stimulation	Sham stimulation	Assessment	Findings
Johann et al. [45]	11	Left DLPFC	1 session	20 trains of 2.5 s	20 Hz	90% MT	Yes	Craving, assessed by VAS	Reduction in craving
Eichhammer et al. [46]	14	Left DLPFC	4 sessions (2 active and 2 sham)	20 trains of 2.5 s	20 Hz	90% MT	Yes (between the group)	Craving, assessed by VAS; cigarettes number	Reduction in consumption
Amiaz et al. [47]	22, 26	Left DLPFC	10 sessions	20 trains of 5 s	10 Hz	100% MT	Yes	Craving, assessed VAS; cigarettes number	Reduction in craving, consumption and dependence
Wing et al. [48]	6, 9	Bilateral DLPFC	20 sessions	50 trains	20 Hz	90% MT	Yes	Craving, assessed by TQSU	Reduction in craving
Rose et al. [49]	15	SFG	3 sessions (1 active 1 Hz, 1 active 10 Hz, 1 MOC)	2.5 min each session (total period of stimulation: 7.5 min)	1 Hz or 10 Hz	90% MT	Yes	Craving, assessed by Shiffman-Jarvik questionnaire and cigarette evaluation questionnaire	Reduction in craving (10 Hz)

Abbreviations: DLPFC = dorsolateral prefrontal cortex, SFG = superior frontal gyrus, MOC = motor cortex, MT = motor threshold, VAS = visual analogue scale, TQSU = Tiffany Questionnaire for Smoking Urges.

Table 2 Summary of the studies on rTMS in the treatment of alcohol addiction										
Study	N subjects (active, sham)	Alcohol use status	Place of stimulation	Number of sessions	Length	Frequency	Intensity of stimulation	Sham stimulation	Assessment	Findings
Mishra et al. [50]	30, 15	After detoxification	Right DLPFC	10 daily sessions	20 trains of 4-9 s	10 Hz	110% MT	Yes	Craving, assessed by ACQ-NOW	Reduction in immediate craving; no effect on craving after 4 weeks
Hoppner et al. [52]	10, 9 (females)	14 days after detoxification	Left DLPFC	10 daily sessions	1000 pulses	20 Hz	90% MT	Yes	Craving, assessed by OCDS; depressive symptoms, assessed by BDI; AB for neutral and alcohol related pictures	No reduction in craving and no effect on mood; increase AB for alcohol related pictures
Herremans et al. [69]	36	After detoxification	Right DLPFC	1 session	40 trains of 1.9 s	20 Hz	110% MT	Yes	Craving, assessed by OCDS	No effect on immediate and long term craving
De Ridder et al. [53]	1 (female)	Active drinking period	dACC	daily sessions during 5 weeks	600 pulses	1 Hz	50% machine output	No	Craving, assessed by VAS	Reduction in immediate craving and consumption; relapse after 3 months with increased craving after 3 months
Abbreviations: DLPFC = dorsolateral prefrontal cortex, dACC = Dorsal anterior cingulate cortex, MT = motor threshold, VAS = visual analogue scale, ACQ-NOW = Alcohol Craving Questionnaire, OCDS = Obsessive Compulsive Drinking Scale, BDI = Beck Depression Inventory, AB = Attentional Blink.										
Table 3 Summary of the studies on rTMS in the treatment of cocaine addiction										
Study	N subjects	Place of stimulation	Number of sessions	Length	Frequency	Intensity of stimulation	Sham stimulation	Assessment	Findings	
Camprodon et al. [54]	6	Bilateral DLPFC	2 sessions	20 trains of 10 s	10 Hz	90% MT	No	Craving, anxiety, happiness, sadness and discomfort, assessed by VAS	Reduction in craving (with right DLPFC rTMS); reduction in anxiety after right-sided rTMS; increase in happiness after right- and in sadness after left-sided rTMS, increase in discomfort equally by left- and right-sided stimulation	
Politi et al. [55]	36	Left DLPFC	10 daily sessions	20 trains of 2 s	15 Hz	100% MT	No	Clinical assessment of craving related symptoms	Reduction in craving	
Abbreviations: DLPFC = dorsolateral prefrontal cortex, MT = motor threshold, VAS = visual analogue scale.										



ing just before and after the rTMS session (on Friday), on Saturday and Sunday during the weekend at home, and on Monday (when the participants returned to the hospital). One high frequency rTMS session delivered to the right DLPFC did not lead to changes in craving (neither immediately after the stimulation session, nor in participants' natural environment during the weekend). This study found that application of a single rTMS session had no significant effect on alcohol craving [51].

In a case-report [53], a 48-year-old woman with a 23-years heavy drinking history was stimulated with low-frequency rTMS targeting the dorsal anterior cingulate cortex (dACC) using a double cone coil in an attempt to suppress very severe alcohol craving. 1 Hz rTMS (50% of the machine's intensity, total of 600 pulses) was delivered for 3 weeks to the medial frontal cortex. It was a combined rTMS neuroimaging study: functional Magnetic Resonance Imaging (fMRI) and resting state electroencephalography (EEG) were performed before rTMS treatments, after successful rTMS and after unsuccessful rTMS with relapse. Blood alcohol volumes were acquired on random days during the treatment course. Alcohol cravings were measured daily by a VAS during a cue exposure. Repetitive rTMS reduced alcohol consumption for the duration of the treatment. Symptoms of withdrawal and cravings were also reduced up to 3 months. This reduction was also reflected with the change in fMRI and EEG activity. After 3 months, the patient relapsed and was treated with 1 week of rTMS. These effects lasted for 3 weeks until the patient relapsed again and the patient became unresponsive to the rTMS treatment [53].

In conclusion, 10 daily sessions of high-frequency rTMS over right DLPFC had significant anti-craving effects in alcohol dependence [50], while a single rTMS session had no significant effect on immediate and long term craving; there were no reduction in craving after high frequency rTMS over left DLPFC [52]; repetitive rTMS targeting the dACC using a double cone coil reduced immediate alcohol craving and consumption [53]. These studies together suggest that rTMS may play a therapeutic role in alcohol dependence, though the evidence is still preliminary [68], and also indicate that one single session could be too short to alter alcohol craving in alcohol-dependent patients. As we can see in Table 2, stimulation parameters, such as frequency, % MT, train duration, intertrain interval and area of stimulation differ significantly among studies. Based on these findings, Her-

remans and Baeken [69] suggested the evaluation of multiple rTMS sessions in larger, randomized, sham-controlled population samples. Furthermore, randomized controlled studies should be done to evaluate whether patients need stimulation with high or low frequency [69].

According to the criteria suggested by Brainin et al. [67], rTMS therapy for alcohol dependence includes one case report [53] (class IV) and three controlled clinical trials (class III) [50–52], two of which reported no effect on craving and one showed reduction in craving. Thus, there is inadequate evidence to confer a level of recommendation for its effectiveness.

### 5.3. rTMS and cocaine

Camprodon and colleagues [54] conducted a preliminary study to examine rTMS as a potential treatment for the craving experienced by cocaine-dependent individuals. They investigated whether a single session of rTMS over DLPFC could reduce cocaine craving among six male participants with cocaine dependence. Secondary endpoints were changes in anxiety, happiness, sadness and discomfort. In this randomized cross-over design, participants were administered two sessions of high frequency (10 Hz) rTMS at 90% of MT, to the right and left DLPFC, with a week break between the two sessions. Patients were asked to complete a set of 15 visual analogue scales (VAS) ranging from “not at all” to “more than ever”. Each VAS evaluated one of the primary or secondary endpoints on three occasions: 10 minutes before the intervention, immediately after, and 4 hours after rTMS session.

The authors found that a single session of high frequency rTMS to the right DLPFC, but not to the left DLPFC, decreased level of craving for cocaine. This is a transient effect that resolves within 4 h after stimulation.

Anxiety resulted significantly reduced after right-sided stimulation. Happiness was increased after right- and sadness after left-sided stimulation. Discomfort was increased equally by left- and right-sided rTMS and the interaction term was not significant, providing a useful control for the non-specific effects of the stimulation.

This research provided the first demonstration that high frequency rTMS applied over the right DLPFC is effective in reducing craving associated with chronic use of cocaine [54]. Also Politi et al. [55] studied the effects of rTMS over the DLPFC on cocaine cravings among 36 cocaine dependent participants studied post-

622 detoxification. Ten daily sessions of high frequency  
623 (15 Hz) rTMS over the left DLPFC at 100% of MT  
624 were administered. The participants underwent daily  
625 clinical assessment of symptoms associated with co-  
626 caine craving. These authors found that the daily ses-  
627 sions of high frequency rTMS of the left DLPFC re-  
628 duced cocaine craving. Cocaine cravings reduced gradu-  
629 ally throughout the sessions [55].

630 As shown in Table 3, both these studies [54,55], us-  
631 ing different paradigms and assessment tools, suggest  
632 that rTMS over the DLPFC can potentially provide an  
633 effective therapeutic intervention for cocaine craving  
634 and addiction. There was a discrepancy in the laterality  
635 of the findings. Further research is required on the op-  
636 timal stimulation patterns and on the exact brain region  
637 to stimulate. Future studies that assess cocaine intake  
638 after treatment are also required. According to the cri-  
639 teria suggested by Brainin et al. [67], studies of rTMS  
640 therapy for cocaine dependence includes one clinical  
641 trial (class III) [54] and one study rated in class IV [55]  
642 that showed reductions in craving. Thus, there is inad-  
643 equate evidence to confer a level of recommendation  
644 for the effectiveness of this treatment.

## 645 6. Conclusion and future studies

646 In summary, in the research that evaluated the ther-  
647 apeutic use of rTMS in addiction we have one clini-  
648 cal trial classified in class II [47] that showed reduc-  
649 tion in craving, consumption and dependence, five tri-  
650 als classified in class III that support the effectiveness  
651 of rTMS [45,46,49,50,54] and two studies in the same  
652 class that reported the ineffectiveness of this treat-  
653 ment [51,52]. Thus, based on the available evidence,  
654 rTMS can be classified as probably effective in the  
655 treatment of addiction. At the moment, the best level  
656 of evidence of the effectiveness of rTMS is in the treat-  
657 ment of nicotine dependence.

658 The effects of rTMS sessions on drug craving and  
659 consumption provide evidence and support for further  
660 TMS studies in the field of addiction research. Most  
661 of the studies that assessed the therapeutic potential  
662 of rTMS to treat alcohol, nicotine and cocaine addic-  
663 tion were performed using a figure-of-eight coil target-  
664 ing DLPFC. These studies show that high frequency  
665 rTMS over the DLPFC can reduce craving and con-  
666 sumption in nicotine, alcohol and cocaine-dependent  
667 populations. These studies are still few and have also  
668 methodological limitations: they were exploratory in  
669 nature and consist of relatively small sample sizes. Fu-

670 ture research should identify the optimal parameters  
671 (appropriate target, intensity, frequency and length) of  
672 stimulation in rTMS studies for the most effective and  
673 safe treatment of drug addiction. Future studies with  
674 multiple rTMS sessions in larger, randomized, sham-  
675 controlled population samples are required.

676 It is important to note that none of these studies  
677 demonstrated complete abstinence from substance use  
678 and few studies [46,52] evaluated craving in the nat-  
679 ural environment of the patients. It also could be that  
680 subjective craving assessment is not that reliable [52].  
681 In addition, the period of rTMS to maintain the gains  
682 produced need to be examined with longer follow-up  
683 studies.

684 Fitzgerald and colleagues review reported that high-  
685 frequency rTMS applied to the left DLPFC is an ef-  
686 fective treatment for patients with major depressive  
687 disorder [70], although the review included only two  
688 studies [52,54] that took in consideration that target-  
689 ing the DLPFC might affect mood. Camprodon et  
690 al. [54] found that in cocaine addicted individuals hap-  
691 piness was increased after right-sided and sadness af-  
692 ter left-sided stimulation [54]. These findings were in  
693 contrast with those from studies of patients with de-  
694 pression, who tend to show the opposite lateraliza-  
695 tion [70,71]. Instead, Hoppner and colleagues [52] did  
696 not find significant differences in mood after real rTMS  
697 over the left DLPFC in individuals with alcohol de-  
698 pendence [52]. Thus, more research is needed on the  
699 impact of rTMS on mood in individuals with alco-  
700 hol and drug dependence. More studies that measure  
701 psychological and neurophysiological variables, such  
702 as frontal activation tasks, quantitative EEG, evoked  
703 potentials and functional Magnetic Resonance, along  
704 with rTMS in addiction are required for more compre-  
705 hensive assessment of the treatment effects. Given the  
706 critical interaction between brain stimulation and cog-  
707 nitive activation revealed in some studies (e.g. Amiaz  
708 et al. [47]), it is possible that a combination of brain  
709 stimulation and cognitive behavioural therapies would  
710 produce a promising clinical outcome [5]. These find-  
711 ings might translate across the spectrum of addictive  
712 disorders [72].

## 713 Acknowledgments

714 This work was supported by the Department of Anti-  
715 Drug Policies of the Italian Presidency of the Coun-  
716 cil of Ministers (DPA). We acknowledge all institu-  
717 tions involved in this study, namely the Addiction De-

partment ULSS 20 of Verona and the Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona. A special thanks is addressed to dr. Catia Seri and dr. Giuseppe Cuoghi (Addiction Department ULSS 20 of Verona) for their help in the preparation of the manuscript.

## References

- [1] R.Z. Goldstein and N.D. Volkow, Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex, *Am J Psychiatry* **159**(10) (2002), 1642–1652.
- [2] American Psychiatric Association (APA), Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision (DSM-IV-TR), American Psychiatric Association, Washington, DC, 2000.
- [3] S.E. Hyman, R.C. Malenka and E.J. Nestler, Neural mechanisms of addiction: The role of reward-related learning and memory, *Ann Rev Neurosci* **29**(1) (2006), 565.
- [4] C.P. O'Brien, Evidence-based treatments of addiction, *Philos Trans R Soc B: Biol Sci* **363**(1507) (2008), 3277–3286.
- [5] J. Feil and A. Zangen, Brain stimulation in the study and treatment of addiction, *Neurosci Biobehav Rev*, 2009.
- [6] T. Wagner, A. Valero-Cabre and A. Pascual-Leone, Noninvasive human brain stimulation, *Annu Rev Biomed Eng* **9**(1) (2007), 527–565.
- [7] M. Hallett, Transcranial magnetic stimulation: A primer, *Neuron* **55**(2) (2007), 187–199.
- [8] F. Rachid and G. Bertschy, Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of depression: A critical appraisal of the last 10 years, *Neurophysiol Clin/Clin Neurophysiol* **36**(3) (2006), 157–183.
- [9] Z. Daskalakis, B. Christensen, P. Fitzgerald and R. Chen, Transcranial magnetic stimulation: A new investigational and treatment tool in psychiatry, *J Neuropsychiatry Clin Neurosci* **14**(4) (2002), 406–415.
- [10] M. Hallett, Transcranial magnetic stimulation: A primer, *Neuron* **55**(2) (2007), 187–199.
- [11] U. Ziemann, TMS induced plasticity in human cortex, *Rev Neurosci* **15**(4) (2004), 253–266.
- [12] E. Wassermann, Risk and safety of repetitive transcranial magnetic stimulation: Report and suggested guidelines from the international workshop on the safety of repetitive transcranial magnetic stimulation, *Electroencephalogr Clin Neurophysiol* **108**(1) (1998), 1–16.
- [13] K. Machii, D. Cohen, C. Ramos-Estebanez and A. Pascual-Leone, Safety of rTMS to non-motor cortical areas in healthy participants and patients, *Clin Neurophysiol* **117**(2) (2006), 455–471.
- [14] Y. Levkovitz, Y. Roth, E. Harel, Y. Braw, A. Sheer and A. Zangen, A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation, *Clin Neurophysiol* **118**(12) (2007), 2730–2744.
- [15] S. Rossi, M. Hallett, P.M. Rossini and A. Pascual-Leone, Safety of tms consensus group. safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research, *Clin Neurophysiol* **120**(12) (2009 Dec), 2008–2039.
- [16] C.K. Loo, T.F. McFarquhar and P.B. Mitchell, A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression, *Int J Neuropsychopharmacol* **11**(01) (2008), 131–147.
- [17] U. Ziemann, S. Lonnecker and W. Paulus, Inhibition of human motor cortex by ethanol a transcranial magnetic stimulation study, *Brain* **118**(6) (1995), 1437–1446.
- [18] S. Kahkonen, M. Kesäniemi, V.V. Nikouline, J. Karhu, M. Ollikainen, M. Holi et al., Ethanol modulates cortical activity: Direct evidence with combined TMS and EEG, *NeuroImage* **14**(2) (2001), 322–328.
- [19] S. Kahkonen, J. Wilenius, V.V. Nikulin, M. Ollikainen and R.J. Ilmoniemi, Alcohol reduces prefrontal cortical excitability in humans: a combined TMS and EEG study, *Neuropsychopharmacology* **28**(4) (2003), 747–754.
- [20] A. Conte, M.L. Attilia, F. Gilio, E. Iacovelli, V. Frasca, C.M. Bettolo, M. Gabriele, E. Giacomelli, M. Prencipe, A. Berardelli, M. Ceccanti and M. Inghilleri, Acute and chronic effects of ethanol on cortical excitability, *Clin Neurophysiol* (2008).
- [21] R. Nardone, J. Bergmann, M. Kronbichler et al., Altered motor cortex excitability to magnetic stimulation in alcohol withdrawal syndrome, *Alcohol Clin Exp Res* **34**(4) (2010 Apr), 628–632.
- [22] N. Lang, A. Hasan, E. Sueske, W. Paulus and M.A. Nitsche, Cortical hypoexcitability in chronic smokers? A transcranial magnetic stimulation study, *Neuropsychopharmacology* **33**(10) (2008), 2517–2523.
- [23] P.B. Fitzgerald, S. Williams and Z.J. Daskalakis, A transcranial magnetic stimulation study of the effects of cannabis use on motor cortical inhibition and excitability, *Neuropsychopharmacology* **34**(11) (2009), 2368–2375.
- [24] M. Oliveri and G. Calvo, Increased visual cortical excitability in ecstasy users: A transcranial magnetic stimulation study, *J Neurol Neurosurg Psychiatry* **74**(8) (2003), 1136–1138.
- [25] N.N. Boutros, S.H. Lisanby, H. Tokuno, M.W. Torello, D. Campbell, R. Berman, R. Malison, J.H. Krystal and T. Kosten, Elevated motor threshold in drugfree, cocaine-dependent patients assessed with transcranial magnetic stimulation, *Biol Psychiatry* **49**(4) (2001), 369–373.
- [26] N.N. Boutros, S.H. Lisanby, D. McClain-Furmanski, G. Oliwa, D. Gooding and T.R. Kosten, Cortical excitability in cocaine-dependent patients: A replication and extension of TMS findings, *J Psychiatr Res* **39**(3) (2005), 295–302.
- [27] K. Sundaresan, U. Ziemann, J. Stanley and N. Boutros, Cortical inhibition and excitation in abstinent cocaine-dependent patients: A transcranial magnetic stimulation study, *Neuroreport* **18**(3) (2007), 289–292.
- [28] P.M. Rossini and S. Rossi, Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential, *Neurology* **68**(7) (2007), 484–488.
- [29] Z. Daskalakis, B. Möller, B. Christensen, P. Fitzgerald, C. Gunraj and R. Chen, The effects of repetitive transcranial magnetic stimulation on cortical inhibition in healthy human subjects, *Exp Brain Res* **174**(3) (2006), 403–412.
- [30] P. Fitzgerald, S. Fountain and Z. Daskalakis, A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition, *Clin Neurophysiol* **117**(12) (2006), 2584–2596.
- [31] M. Kanno, M. Matsumoto, H. Togashi, M. Yoshioka and Y. Mano, Effects of acute repetitive transcranial magnetic stimulation on dopamine release in the rat dorsolateral striatum, *J Neurol Sci* **217**(1) (2004), 73–81.
- [32] M.E. Keck, T. Welt, M.B. Möller, A. Erhardt, F. Ohl, N. Toschi et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and meso-

- 841 triatal system, *Neuropharmacology* **43**(1) (2002), 101–109.
- 842 [33] A.P. Strafella, T. Paus, J. Barrett and A. Dagher, Repetitive  
843 transcranial magnetic stimulation of the human prefrontal cor-  
844 tex induces dopamine release in the caudate nucleus, *J Neu-  
845 rosci* **21** (2001), RC157.
- 846 [34] S.S. Cho and A.P. Strafella, rTMS of the left dorsolateral pre-  
847 frontal cortex modulates dopamine release in the ipsilateral  
848 anterior cingulate cortex and orbitofrontal cortex, *PLoS One*  
849 **4**(8) (2009 Aug 21), e6725.
- 850 [35] P. Fitzgerald, A. Sritharan, Z. Daskalakis, A. de Castella,  
851 J. Kulkarni and G. Egan, A functional magnetic resonance  
852 imaging study of the effects of low frequency right prefrontal  
853 transcranial magnetic stimulation in depression, *J Clin Psy-  
854 chopharmacol* **27**(5) (2007), 488–492.
- 855 [36] M. Bortolomasi, A. Minelli, G. Fuggetta, M. Perini, S.  
856 Comencini, A. Fiaschi and P. Manganotti, Long-lasting ef-  
857 fects of high frequency repetitive transcranial magnetic stim-  
858 ulation in major depressed patients, *Psychiatry Res* **150**(2)  
859 (2007 Mar 30), 181–186.
- 860 [37] S. Kito, K. Fujita and Y. Koga, Regional cerebral blood flow  
861 changes after lowfrequency transcranial magnetic stimula-  
862 tion of the right dorsolateral prefrontal cortex in treatment-  
863 resistant depression, *Neuropsychobiology* **58**(1) (2008).
- 864 [38] S.H. Lisanby, M.M. Husain, P.B. Rosenquist, D. Maixner, R.  
865 Gutierrez, A. Krystal et al., Daily left prefrontal repetitive  
866 transcranial magnetic stimulation in the acute treatment of  
867 major depression: Clinical predictors of outcome in a multi-  
868 site, randomized controlled clinical trial, *Neuropsychophar-  
869 macology* **34**(2) (2008), 522–534.
- 870 [39] B.D. Greenberg, U. Ziemann, G. Cora-Locatelli, A. Harmon,  
871 D.L. Murphy, J.C. Keel et al., Altered cortical excitability in  
872 obsessive-compulsive disorder, *Neurology* **54**(1) (2000), 142–  
873 147.
- 874 [40] Alonso et al., 2001.
- 875 [41] S.H. Lee, W. Kim, Y.C. Chung, K.H. Jung, W.M. Bahk, T.Y.  
876 Jun et al., A double blind study showing that two weeks of  
877 daily repetitive TMS over the left or right temporoparietal cor-  
878 tex reduces symptoms in patients with schizophrenia who are  
879 having treatment-refractory auditory hallucinations, *Neurosci  
880 Lett* **376**(3) (2005), 177–181.
- 881 [42] Y. Jin, S.G. Potkin, A.S. Kemp, S.T. Huerta, G. Alva, T.M.  
882 Thai et al., Therapeutic Effects of Individualized alpha fre-  
883 quency transcranial magnetic stimulation ( $\alpha$ TMS) on the  
884 negative symptoms of schizophrenia, *Schizophr Bull* **32**(3)  
885 (2006), 556–561.
- 886 [43] N. Goyal, S.H. Nizamie and P. Desarkar, Efficacy of adjuvant  
887 high frequency repetitive transcranial magnetic stimulation on  
888 negative and positive symptoms of schizophrenia: Preliminary  
889 results of a double-blind sham-controlled study, *J Neuropsychi-  
890 atry Clin Neurosci* **19**(4) (2007 Fall), 464–467.
- 891 [44] A. Stanford, Z. Sharif, C. Corcoran, N. Urban, D. Malaspina  
892 and S. Lisanby, rTMS strategies for the study and treatment of  
893 schizophrenia: A review, *Int J Neuropsychopharmacol* **11**(4)  
894 (2008), 563–576.
- 895 [45] M. Johann, R. Wiegand, A. Kharraz, G. Bobbe, G. Sommer,  
896 G. Hajak et al., Repetitive transcranial magnetic stimulation  
897 in nicotine dependence, *Psychiatr Prax* **30** (2003), 129–131.
- 898 [46] P. Eichhammer, M. Johann, A. Kharraz, H. Binder, D. Pittrow,  
899 N. Wodarz et al., High-frequency repetitive transcranial mag-  
900 netic stimulation decreases cigarette smoking, *J Clin Psychi-  
901 atry* **64** (2003), 951–953.
- 902 [47] R. Amiaz, D. Levy, D. Vainiger, L. Grunhaus and A. Zan-  
903 gen, Repeated high-frequency transcranial magnetic stimula-  
904 tion over the dorsolateral prefrontal cortex reduces cigarette  
905 craving and consumption, *Addiction* **104**(4) (2009), 653–660.
- 906 [48] V.C. Wing, I. Bacher, B. Wu, Z.J. Daskalakis and T.P. George,  
907 Effects of high frequency repetitive transcranial magnetic  
908 stimulation on tobacco craving in schizophrenia, *Schizophre-  
909 nia Research* (2012).
- 910 [49] J.E. Rose, F.J. McClernon, B. Froeliger, F.M. Behm, X.  
911 Preud'homme and A.D. Krystal, Repetitive transcranial mag-  
912 netic stimulation of the superior frontal gyrus modulates crav-  
913 ing for cigarettes, *Biological Psychiatry* **70**(8) (2011 Oct 15),  
914 794e9.
- 915 [50] B.R. Mishra, S.H. Nizamie, B. Das and S.K. Praharaj, Effi-  
916 cacy of repetitive transcranial magnetic stimulation in alco-  
917 hol dependence: A sham-controlled study, *Addiction* **105**(1)  
918 (2010 Jan), 49–55.
- 919 [51] S.C. Herremans, C. Baeken, N. Vanderbruggen, M.A. Vander-  
920 hasselt, D. Zeeuws, L. Santermans and R. De Raedt, No influ-  
921 ence of one right-sided prefrontal HF-rTMS session on alco-  
922 hol craving in recently detoxified alcohol-dependent patients:  
923 Results of a naturalistic study, *Drug Alcohol Depend* (2011  
924 Aug).
- 925 [52] J. Höppner, T. Broese, L. Wendler, C. Berger and J. Thome,  
926 Repetitive transcranial magnetic stimulation (rTMS) for treat-  
927 ment of alcohol dependence, *The World Journal of Biological  
928 Psychiatry* **12** (2011), 57–62.
- 929 [53] D. De Ridder, S. Vanneste, S. Kovacs, S. Sunaert and G. Dom,  
930 Transient alcohol craving suppression by rTMS of dorsal an-  
931 terior cingulate: An fMRI and LORETA EEG study, *Neuro-  
932 science Letters* **496** (2011), 5–10.
- 933 [54] J.A. Camprodon, J. Martinez-Raga, M. Alonso, M.C. Shih  
934 and A. Pascual-Leone, One session of high frequency repeti-  
935 tive transcranial magnetic stimulation (rTMS) to the right pre-  
936 frontal cortex transiently reduces cocaine craving, *Drug Alco-  
937 hol Depend* **86** (2007), 91–94.
- 938 [55] E. Politi, E. Fauci, A. Santoro and E. Smeraldi, Daily sessions  
939 of transcranial magnetic stimulation to the left prefrontal cor-  
940 tex gradually reduce cocaine craving, *The American Journal  
941 on Addictions* **17** (2008), 345–346.
- 942 [56] S.E. Hyman, R.C. Malenka and E.J. Nestler, Neural mecha-  
943 nisms of addiction: The role of reward-related learning and  
944 memory, *Ann Rev Neurosci* **29**(1) (2006), 565.
- 945 [57] L.J.M.J. Vanderschuren and P.W. Kalivas, Alterations in  
946 dopaminergic and glutamatergic transmission in the induction  
947 and expression of behavioral sensitization: A critical review of  
948 preclinical studies, *Psychopharmacology* **151**(2) (2000), 99–  
949 120.
- 950 [58] M.E. Wolf, X. Sun, S. Mangiavacchi and S.Z. Chao, Psy-  
951 chomotor stimulants and neuronal plasticity, *Neuropharma-  
952 cology* **47**(Supplement 1) (2004).
- 953 [59] P.W. Kalivas and C. O'Brien, Drug addiction as a pathology  
954 of staged neuroplasticity, *Neuropsychopharmacology* **33**(1)  
955 (2007), 166–180.
- 956 [60] J.A. Kauer and R.C. Malenka, Synaptic plasticity and addic-  
957 tion, *Nat Rev Neurosci* **8** (11) (2007), 844–858.
- 958 [61] B. Everitt, D. Belin, D. Economidou, Y. Pelloux, J. Dalley  
959 and T. Robbins, Neural mechanisms underlying the vulnera-  
960 bility to develop compulsive drug-seeking habits and addic-  
961 tion, *Philos Trans R Soc Lond B Biol Sci* **363**(1507) (2008),  
962 3125–3135.
- 963 [62] A.E. Rorie and W.T. Newsome, A general mechanism for  
964 decision-making in the human brain? *Trends Cogn Sci* **9**  
965 (2005), 41–43.
- 966 [63] S.H. Mitchell, Measuring impulsivity and modeling its associ-

- 967 ation with cigarette smoking, *Behavioral and Cognitive Neuro-*  
968 *science Reviews* **3**(4) (2004), 261–275.
- 969 [64] D. Knoch, L.R. Gianotti, A. Pascual-Leone, V. Treyer, M. Re-  
970 gard, M. Hohmann and P. Brugger, Disruption of right pre-  
971 frontal cortex by low-frequency repetitive transcranial mag-  
972 netic stimulation induces risk-taking behavior, *The Journal of*  
973 *Neuroscience* **26** (2006), 6469–6472.
- 974 [65] M.S. Barr, P.B. Fitzgerald, F. Farzan, T.P. George and Z.J.  
975 Daskalakis, Transcranial magnetic stimulation to understand  
976 the pathophysiology and treatment of substance use disorders,  
977 *Curr Drug Abuse Rev* **11**(3) (2008 Nov), 328–339.
- 978 [66] V.C. Wing, M.S. Barr, C.E. Wass, N. Lipsman, A.M. Lozano,  
979 Z.J. Daskalakis and T.P. George, Brain stimulation methods  
980 to treat tobacco addiction, *Brain Stimul* **9** (2012 Jul).
- 981 [67] M. Brainin, M. Barnes, J.C. Baron, N.E. Gilhus, R. Hughes,  
982 K. Selmaj and G. Waldemar, Guideline Standards Subcom-  
983 mittee of the EFNS Scientific Committee, Guidance for the  
984 preparation of neurological management guidelines by EFNS  
985 scientific task forces – revised recommendations 2004, *Eur J*  
*Neurol* **11**(9) (2004 Sep), 577–581.
- [68] R. Nardone et al., Non-invasive brain stimulation in the func-  
986 tional evaluation of alcohol effects and in the treatment of al-  
987 cohol craving: A review, *Neurosci Res* (2012).  
988
- [69] S.C. Herremans and C. Baeken, The current perspective of  
989 neuromodulation techniques in the treatment of alcohol ad-  
990 diction: A systematic review, *Psychiatr Danub* **24**(Suppl 1)  
991 (2012 Sep), S14–S20.  
992
- [70] P.B. Fitzgerald and Z.J. Daskalakis, A practical guide to the  
993 use of repetitive transcranial magnetic stimulation in the treat-  
994 ment of depression, *Brain Stimul* **5**(3) (2012 Jul), 287–96.  
995
- [71] A.A. Gershon, P.N. Dannon and L. Grunhaus, Transcranial  
996 magnetic stimulation in the treatment of depression, *Am J*  
997 *Psychiatry* **160** (2003), 834–835.  
998
- [72] M.S. Barr, F. Farzan, V.C. Wing, T.P. George, P.B. Fitzgerald  
999 and Z.J. Daskalakis, Repetitive transcranial magnetic stimula-  
1000 tion and drug addiction, *Int Rev Psychiatry* **23**(5) (2011 Oct),  
1001 454–466.  
1002  
1003